Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia.
Journal
American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369
Informations de publication
Date de publication:
01 08 2021
01 08 2021
Historique:
revised:
24
04
2021
received:
25
12
2020
accepted:
25
04
2021
pubmed:
29
4
2021
medline:
22
9
2021
entrez:
28
4
2021
Statut:
ppublish
Résumé
Comparative data guiding initial therapy for Waldenström macroglobulinemia (WM), an infrequently encountered non-Hodgkin lymphoma, are sparse. We evaluated three commonly used rituximab-based frontline regimens: rituximab-bendamustine (R-Benda); dexamethasone, rituximab, cyclophosphamide (DRC); and bortezomib, dexamethasone, rituximab (BDR) in 220 treatment-naïve patients with WM, seen at Mayo Clinic between November 1, 2000 and October 31, 2019. The median follow-up was 4.5 (95%CI: 4-5) years. The R-Benda cohort (n = 83) demonstrated superior overall response rate (ORR: 98%), in comparison to DRC (n = 92, ORR: 78%) or BDR (n = 45, ORR: 84%) cohorts, p = 0.003. Similarly, longer progression-free survival (PFS) was evident with R-Benda use [median 5.2 vs. 4.3 (DRC) and 1.8 years (BDR), p < 0.001]. The time-to-next therapy (TTNT) favored R-Benda [median, not-reached, 4.4 (DRC) and 2.6 years (BDR), p < 0.001). These endpoints were comparable between the DRC and BDR cohorts. Overall survival (OS) was similar across the three cohorts, p = 0.77. In a subset analysis of 142 patients genotyped for MYD88
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
945-953Subventions
Organisme : NCATS NIH HHS
ID : KL2 TR002379
Pays : United States
Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Kapoor P, Ansell SM, Fonseca R, et al. Diagnosis and management of Waldenstrom macroglobulinemia: mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines 2016. JAMA Oncol. 2017;3(9):1257-1265.
Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390.
Tohidi-Esfahani I, Warden A, Malunis E, et al. Whimsical (Waldenstrom's macroglobulinemia study involving CArt-wheeL): a global patient-derived data registry capturing treatment, quality of life and COVID-19 data. Blood. 2020;136(Supplement 1):30-31.
Buske C, Sadullah S, Kastritis E, et al. Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review. Lancet Haematol. 2018;5(7):e299-e309.
Dimopoulos MA, Tedeschi A, Trotman J, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenström's macroglobulinemia. N Engl J Med. 2018;378(25):2399-2410.
Buske C, Tedeschi A, Trotman J, et al. Five-year follow-up of Ibrutinib plus rituximab vs placebo plus rituximab for Waldenstrom's macroglobulinemia: final analysis from the randomized phase 3 iNNOVATETM study. Blood. 2020;136(Supplement 1):24-26.
Leblond V, Johnson S, Chevret S, et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenstrom macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol. 2013;31(3):301-307.
Zanwar S, Abeykoon JP, Kapoor P. Novel treatment strategies in the management of Waldenstrom macroglobulinemia. Curr Hematol Malig Rep. 2020;15(1):31-43.
Owen RG, Kyle RA, Stone MJ, et al. Response assessment in Waldenström macroglobulinaemia: update from the VIth international workshop. Br J Haematol. 2013;160(2):171-176.
Xu L, Hunter ZR, Yang G, et al. MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013;121(11):2051-2058.
Ondrejka SL, Lin JJ, Warden DW, Durkin L, Cook JR, Hsi ED. MYD88 L265P somatic mutation: its usefulness in the differential diagnosis of bone marrow involvement by B-cell lymphoproliferative disorders. Am J Clin Pathol. 2013;140(3):387-394.
Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691-4695.
Kaplan ELMP. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
Wang M, Shah NN, Alencar AJ, et al. LOXO-305, a next generation, highly selective, non-covalent BTK inhibitor in previously treated mantle cell lymphoma, Waldenström's macroglobulinemia, and other non-Hodgkin lymphomas: results from the phase 1/2 BRUIN study. Blood. 2020;136(Supplement 1):8-10.
Abeykoon JP, Yanamandra U, Kapoor P. New developments in the management of Waldenstrom macroglobulinemia. Cancer Manag Res. 2017;9:73-83.
Sekhar J, Sanfilippo K, Zhang Q, Trinkaus K, Vij R, Morgensztern D. Waldenström macroglobulinemia: a surveillance, epidemiology, and end results database review from 1988 to 2005. Leuk Lymphoma. 2012;53(8):1625-1626.
Buske C, Dimopoulos MA, Grunenberg A, et al. Bortezomib in combination with dexamethasone, rituximab and cyclophosphamide (B-DRC) as first - line treatment of Waldenstrom's macroglobulinemia: results of a prospectively randomized multicenter European phase II trial. Blood. 2020;136(Supplement 1):26-26.
Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203-1210.
Ansell SM, Kyle RA, Reeder CB, et al. Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc. 2010;85(9):824-833.
Arulogun SO, Brian D, Goradia H, et al. Bendamustine plus rituximab for the treatment of Waldenström macroglobulinaemia: patient outcomes and impact of bendamustine dosing. Blood. 2020;136(Supplement 1):10-11.
Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol. 2007;25(22):3344-3349.
Kastritis E, Gavriatopoulou M, Kyrtsonis M-C, et al. Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study. Blood. 2015;126(11):1392-1394.
Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol. 2009;27(23):3830-3835.
Dimopoulos MA, García-Sanz R, Gavriatopoulou M, et al. Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European myeloma network (EMN). Blood. 2013;122(19):3276-3282.
Castillo JJ, Gustine JN, Meid K, et al. Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia. Br J Haematol. 2018;181(1):77-85.
Rummel MJ, Lerchenmüller C, Hensel M, et al. Two years rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with Waldenström's macroglobulinemia (MW): results of a prospective, randomized, multicenter phase 3 study (the StiL NHL7-2008 MAINTAIN trial). Blood. 2019;134(Supplement_1):343-343.
Zanwar S, Abeykoon JP, Gertz MA, et al. Rituximab-based maintenance therapy in Waldenström macroglobulinemia: a case control study. J Clin Oncol. 2019;37(15_suppl):7559-7559.
Castillo JJ, Gustine JN, Keezer A, et al. Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia. Am J Hematol. 2020;95(4):372-378.
Paludo J, Abeykoon JP, Shreders A, et al. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. Ann Hematol. 2018;97(8):1417-1425.
Laribi K, Poulain S, Willems L, et al. Bendamustine plus rituximab in newly-diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO). Br J Haematol. 2019;186(1):146-149.
Kapoor P, Treon SP. The race to stymie BTK: zanu zings. Blood. 2020;136(18):1997-1999.
Trotman J, Opat S, Gottlieb D, et al. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. Blood. 2020;136(18):2027-2037.
Dimopoulos M, Sanz RG, Lee H-P, et al. Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. Blood Adv. 2020;4(23):6009-6018.
Martin P, Chen Z, Cheson BD, et al. Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma. Br J Haematol. 2017;178(2):250-256.
Miguel JFS, Richardson PG, Orlowski RZ, et al. Risk of second primary malignancies (SPMs) following bortezomib (Btz)-based therapy: analysis of four phase 3 randomized controlled trials in previously untreated or relapsed multiple myeloma (MM). Blood. 2011;118(21):2933-2933.
Leblond V, Kastritis E, Advani R, et al. Treatment recommendations from the eighth international workshop on Waldenström's macroglobulinemia. Blood. 2016;128(10):1321-1328.
Kapoor P, Gertz MA, Ansell SM. Fitting mSMART into the current clinical management of Waldenström macroglobulinemia-reply. JAMA Oncol. 2018;4(5):745-746.